Group 1 - The company plans to place 14.4 million shares, representing approximately 3.20% of the total issued shares after the placement [1] - The placement price is set at HKD 4.33 per share, which is a discount of about 18.76% compared to the closing price of HKD 5.33 on September 9 [1] - The total expected proceeds from the placement are approximately HKD 62.35 million, with net proceeds estimated at around HKD 59.34 million [1] Group 2 - The net proceeds will be allocated as follows: 40% for clinical development of pipeline assets TST001 and TST002 [1] - 30% will be used to advance promising preclinical pipeline assets with near-term licensing potential, including TST801, TST013, and TST786 [1] - The remaining 30% will be allocated for working capital and general purposes to enhance the company's financial stability, including general business operations and development [1]
创胜集团-B拟折让约18.76%配售1440万股 净筹约5934万港元